New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
07:40 EDTCELGCelgene weakness has created attractive entry point, says Stifel
Stifel expects the outcome of the Revlimid Markman hearing in July to help lift an overhang on Celgene, and the firm expects the company to have an overall strong presence at ASCO at the end of May. Stifel keeps a Buy rating on the stock.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent CELG news | >>
May 1, 2015
07:36 EDTCELGCelgene says analysis of Revlimid in non-del-5Q-MDS showed improved QOL measures
Subscribe for More Information
April 30, 2015
16:01 EDTCELGOptions Update; April 30, 2015
iPath S&P 500 VIX Short-Term Futures up 60c to 21.84. Option volume leaders: AAPL TSLA TWTR GILD FB AMZN CELG VZ KMI according to Track Data.
10:46 EDTCELGLeerink biotech analyst holds an analyst/industry conference call
Biotech Analyst Liang, along with Dr. Alan List an MDS Specialist, provide an update on the myelodysplastic syndrome pipeline on an Analyst/Industry conference call to be held on May 5 at 2:30 pm.
09:18 EDTCELGOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: Glu Mobile (GLUU), up 28.2% after reporting first quarter results and deals with Tencent and Britney Spears... Civeo (CVEO), up 3.05... TASER (TASR), up 9.6%... Virgin America (VA), up 2.7%... Noble Corp (NE), up 1.8%... Statoil (STO), up 2.8%... Alpha Natural (ANR), up 3.6%... Exxon Mobil (XOM), up 1.4%... Phillips 66 (PSX), up 1.2%... NXP Semiconductors (NXPI), up 2.4%. ALSO HIGHER: Clicksoftware (CKSW), up 27.8% after being acquired by Francisco Partners... JetBlue (JBLU), up 1.4% after being upgraded to Outperform from Neutral at Credit Suisse... WuXi PharmaTech (WX), up 16.5% after receiving going private proposal. DOWN AFTER EARNINGS: Yelp (YELP), down 17.1%... Celgene (CELG), down 2.4%... STMicroelectronics (STM), down 11.4%... Harman International (HAR), down 9%... Potash (POT), down 2.4%... Generac (GNRC), down 7%... Nokia (NOK), down 8.7%... Baidu (BIDU), down 2.6%. ALSO LOWER: Inovio Pharmaceuticals (INO), down 18.1% after 9.5M share Spot Secondary priced at $8.00... Miller Energy (MILL), down 9% after receiving 'Wells Notice'... Scorpio Tankers (STNG), down 7.5% after 15M share Spot Secondary priced at $9.30... Advaxis (ADXS), down 6% after 2.8M share Spot Secondary priced at $19.00.
09:14 EDTCELGOn The Fly: Pre-market Movers.
Subscribe for More Information
09:05 EDTCELGCelgene receives orphan status for lymphoma treatment
The FDA granted Celgene for its treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, Revlimid.
09:04 EDTCELGCelgene receives orphan status for lymphoma treatment
07:44 EDTCELGAcceleron, Celgene select Luspatercept to advance to Phase 3
Acceleron Pharma (XLRN) announced that Acceleron and its collaboration partner, Celgene Corporation (CELG), plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015. The companies will continue to develop sotatercept for patients with chronic kidney disease. Preliminary data from the ongoing phase 2 clinical trial of luspatercept in patients with lower risk MDS will be presented by Uwe Platzbecker, M.D., University Hospital in Dresden, Germany, in the oral session “Best of Clinical Trials II” at the MDS Foundation 13th International Symposium on Myelodysplastic Syndromes on Saturday May 2, 2015, at 10:30 AM at the Washington Marriott Wardman Park Hotel in Washington, D.C.
07:32 EDTCELGCelgene reaffirms FY15 adjusted EPs view $4.60-$4.75, consensus $4.81
Reaffirms total net product sales $9B-$9.5B, consensus $9.32B. REVLIMID® net sales are expected to be in the range of $5,600 million to $5,700 million ABRAXANE® net sales are expected to be in the range of $1,000 million to $1,250 million
07:32 EDTCELGCelgene reports Q1 adjusted EPS $1.07, consensus $1.06
Subscribe for More Information
April 29, 2015
15:00 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
07:16 EDTCELGAgios Pharmaceuticals plans to advance AG-881 to clinical development
Subscribe for More Information
April 28, 2015
05:53 EDTCELGStocks with implied volatility movement; AMGN CELG
Subscribe for More Information
April 27, 2015
07:31 EDTCELGCelgene to acquire Quanticel Pharmaceuticals for $100M in cash
Subscribe for More Information
April 26, 2015
12:50 EDTCELGApple, Celgene, others are 'top picks' for spring, Barron's says
In a survey of U.S. money managers, shares of Apple (AAPL), Dow Chemical (DOW), American Airlines (AAL), Celgene (CELG), General Motors (GM), and McDermott (MDR) were identified as top picks for this spring, Barron's contends in its cover story. Reference Link
April 24, 2015
10:59 EDTCELGCelgene call activity attributed to vague takeover speculation
Subscribe for More Information
10:22 EDTCELGRumor: Celgene active on vague takeover speculation
Celgene (CELG) shares are active on speculation Bristol-Myers (BMY) may be interested in acquiring the company.
05:39 EDTCELGCelgene announces strategic collaboration with AstraZeneca
Subscribe for More Information
April 23, 2015
17:45 EDTCELGCelgene announces fulfillment of approval requirements for POMALYST
Subscribe for More Information
09:20 EDTCELGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1–10 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The ’501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
1 | 2 | all recent CELG news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use